ClearNote Health advanced its pancreatic cancer early-detection franchise with updated assay performance presented at AACR. The company said adding a glycan biomarker (CA19-9) to its core 5-hydroxymethylcytosine (5hmC) and cfDNA fragment-size genotyping approach improved sensitivity in high-risk validation cohorts while holding specificity at 97.5%. The updates also included performance assessments across additional validation settings, including cohorts with new-onset type 2 diabetes and other risk factors, with the company reporting no major performance differences so far across these groups. For early detection developers, the emphasis remains on maintaining high specificity while improving stage I sensitivity. In a separate commercialization step, Karius and Mayo Clinic Laboratories expanded ordering access for Karius’s plasma and BAL metagenomic infectious disease tests through Mayo Clinic Labs. The move provides another distribution channel for metagenomic diagnostics in clinical workflows.